Two new studies from researchers at Fred Hutchinson Cancer Center reveal how bacteria infiltrate tumors and could be helping tumors progress and spread. The research team also showed that the different microbial players in a tumor’s microbiome could influence how a cancer responds to treatment.
Researchers at Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy successfully trained a machine learning algorithm to predict, in hindsight, which patients with melanoma would respond to treatment and which would not, in a small study.
Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed an automated system to calculate metabolic tumor volume in diffuse large B-cell lymphoma. These findings could make it easier to calculate tumor volume for clinical trials and possibly patient care.
In a phase Ib trial, led by Naval Daver and Michael Andreeff at MD Anderson Cancer Center, researchers evaluated the combination of Venclexta (venetoclax) and idasanutlin in 56 patients with R/R AML who were unfit for chemotherapy. IDH1/2 and RUNX1 mutations were associated with higher composite complete remission rates of 50% and 45%, respectively, and were linked to therapy sensitivity.
MD Anderson Cancer Center researchers used both clinical samples and laboratory models to demonstrate that higher levels of a specific mucin-degrading bacteria are associated with a higher incidence of febrile neutropenia and that treatment with antibiotics helped restore those levels to normal.
BET inhibitors, a class of drugs already in clinical trials, might work especially well in breast cancer patients who have acquired a Y537S mutation, according to a preclinical study led by researchers at UT Southwestern Medical Center.
A study led by researchers from NYU Grossman School of Medicine and UC San Diego Moores Cancer Center linked the extent of genomic loss of region 9p24 on chromosome 9 in the cancer cells of patients with HPV-negative head and neck squamous cell carcinoma to survival duration after checkpoint inhibitor therapy.
A new study led by a University of Cincinnati researcher provides more clarity on how immunotherapy treatment for patients with cancer affects COVID-19 severity.
Duke Health researchers have identified a unique process within the environment of glioblastoma brain tumors that drives resistance to immune-boosting therapies and could be targeted to promote the effects of those drugs.
A large study by researchers at the American Cancer Society demonstrated that adult cancer survivors, particularly those diagnosed within five years and/or those who have a history of chemotherapy, have an increased risk for bone fractures, specifically pelvic and vertebral fractures, compared to older adults without cancer.
